IN2014CN04055A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04055A IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
- Authority
- IN
- India
- Prior art keywords
- proportion
- composition
- increased
- disease
- treat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 4
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001657523 Coriobacteriaceae Species 0.000 abstract 1
- 241001608234 Faecalibacterium Species 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 229920001100 Polydextrose Polymers 0.000 abstract 1
- 241001430183 Veillonellaceae Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 244000005709 gut microbiome Species 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940035035 polydextrose Drugs 0.000 abstract 1
- 235000013856 polydextrose Nutrition 0.000 abstract 1
- 239000001259 polydextrose Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
- A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555800P | 2011-11-04 | 2011-11-04 | |
| PCT/US2012/063008 WO2013067146A1 (en) | 2011-11-04 | 2012-11-01 | Methods and compositions for modulating gastrointestinal bacteria to promote health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04055A true IN2014CN04055A (enrdf_load_stackoverflow) | 2015-10-23 |
Family
ID=48192757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4055CHN2014 IN2014CN04055A (enrdf_load_stackoverflow) | 2011-11-04 | 2012-11-01 |
Country Status (11)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201312713D0 (en) * | 2013-03-22 | 2013-08-28 | Weaver Connie M | Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption |
| EP4529950A3 (en) | 2014-10-31 | 2025-08-20 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| AU2016250159A1 (en) * | 2015-04-14 | 2017-11-09 | Psomagen, Inc. | Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions |
| EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
| GB201519088D0 (en) * | 2015-10-28 | 2015-12-09 | Metabogen Ab | The use of bacteria formulations |
| US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
| EP3199170B1 (en) * | 2016-01-26 | 2021-07-28 | FUJIFILM Corporation | Salacia for reducing the number of intestinal bacteria, food, and pharmaceutical product thereof |
| CN109069521A (zh) * | 2016-03-14 | 2018-12-21 | 物产食品科技股份有限公司 | 粪杆菌属细菌增殖剂 |
| EP3511406A4 (en) * | 2016-09-06 | 2020-04-01 | BGI Shenzhen | FAECALIBACTERIUM LONGUM AND ASSOCIATED APPLICATION |
| CN115919952A (zh) | 2017-06-02 | 2023-04-07 | 古德盖特公司 | 用于治疗生态失调的葡萄皮 |
| CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| EP3466417A1 (en) * | 2017-10-04 | 2019-04-10 | Sorbonne Université | Compounds for the prevention and treatment of glucose intolerance related conditions and obesity |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| CN109998112B (zh) * | 2017-12-22 | 2024-05-14 | 奥地利商艾尔柏有限公司 | 红蝽杆菌纲促进肠道健康的用途 |
| EP3752167A1 (en) * | 2018-02-14 | 2020-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polydextrose for the treatment of inflammatory diseases |
| US20210239696A1 (en) * | 2018-05-09 | 2021-08-05 | Carbiotix Ab | Method for measuring and improving gut health |
| EP3808357B1 (en) * | 2018-05-31 | 2025-03-26 | BGI Shenzhen | Composition comprising megamonas funiformis and anaerofustis stercorihominis and use thereof |
| AU2019306649A1 (en) | 2018-07-19 | 2021-02-04 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| WO2020051379A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| ES2763874B2 (es) * | 2018-11-30 | 2020-10-13 | Consejo Superior Investigacion | Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades |
| CA3153884A1 (en) * | 2019-10-07 | 2021-04-15 | Nikole KIMES | Therapeutic pharmaceutical compositions |
| KR102174095B1 (ko) * | 2019-12-11 | 2020-11-05 | 주식회사 에이치이엠 | 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 |
| CA3175308A1 (en) * | 2020-03-13 | 2021-09-16 | Fitbiomics Inc. | Probiotic compositions for improving human health and athletic performance |
| JP2021168651A (ja) * | 2020-04-16 | 2021-10-28 | サンスター株式会社 | フィーカリバクテリウム属細菌増殖用組成物、酪酸産生増加用組成物、及び腸内環境改善用組成物 |
| CN117119907A (zh) * | 2021-05-06 | 2023-11-24 | 雀巢产品有限公司 | 使用肌醇、赤藓糖醇或山梨糖醇中的至少一种来增强普拉梭菌生长的组合物和方法 |
| WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0394655A (ja) * | 1989-09-06 | 1991-04-19 | Otsuka Pharmaceut Co Ltd | 栄養補給用組成物 |
| JP4328473B2 (ja) * | 2001-04-09 | 2009-09-09 | 雪印乳業株式会社 | 肥満予防改善飲食品 |
| FI20020078A7 (fi) * | 2002-01-15 | 2003-07-16 | Danisco | Immuunijärjestelmän stimulointi polydextroosilla |
| JP2003334025A (ja) * | 2002-05-15 | 2003-11-25 | Toyo Shinyaku:Kk | 健康食品 |
| DE60330781D1 (de) * | 2002-08-06 | 2010-02-11 | Danisco | Anwendung von lactobacillus zur herstellung von exopolysacchariden in nahrungsmittel und pharmazeutische zusammensetzungen |
| GB0302872D0 (en) * | 2003-02-10 | 2003-03-12 | Univ Liverpool | Treatment of inflammatory bowel disease |
| JP2010527613A (ja) * | 2007-05-23 | 2010-08-19 | テイト アンド ライル イングレディエンツ アメリカス インコーポレイテッド | 遅消化性または消化抵抗性オリゴ糖組成物を含んでなる食用組成物 |
| GB0903016D0 (en) * | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| JP6077303B2 (ja) * | 2009-05-07 | 2017-02-08 | タト エ リル アングルディアント フランス ソシエテ パ アクシオンス シンプリフィエ | アルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランを含有する組成物及びアルファ−（１，２）−分岐アルファ−（１，６）オリゴデキストランの製造方法 |
-
2012
- 2012-11-01 IN IN4055CHN2014 patent/IN2014CN04055A/en unknown
- 2012-11-01 JP JP2014540070A patent/JP2014532710A/ja active Pending
- 2012-11-01 EP EP12845672.0A patent/EP2773357A4/en not_active Withdrawn
- 2012-11-01 BR BR112014010660A patent/BR112014010660A2/pt not_active IP Right Cessation
- 2012-11-01 MX MX2014005433A patent/MX2014005433A/es not_active Application Discontinuation
- 2012-11-01 CA CA2854398A patent/CA2854398A1/en not_active Abandoned
- 2012-11-01 AU AU2012332491A patent/AU2012332491A1/en not_active Abandoned
- 2012-11-01 CN CN201280064861.5A patent/CN104159588A/zh active Pending
- 2012-11-01 KR KR1020147014663A patent/KR20140093252A/ko not_active Withdrawn
- 2012-11-01 WO PCT/US2012/063008 patent/WO2013067146A1/en active Application Filing
- 2012-11-01 US US14/355,963 patent/US20150209383A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104159588A (zh) | 2014-11-19 |
| US20150209383A1 (en) | 2015-07-30 |
| EP2773357A4 (en) | 2015-08-26 |
| EP2773357A1 (en) | 2014-09-10 |
| JP2014532710A (ja) | 2014-12-08 |
| MX2014005433A (es) | 2014-08-22 |
| WO2013067146A1 (en) | 2013-05-10 |
| KR20140093252A (ko) | 2014-07-25 |
| CA2854398A1 (en) | 2013-05-10 |
| BR112014010660A2 (pt) | 2017-05-09 |
| AU2012332491A1 (en) | 2014-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04055A (enrdf_load_stackoverflow) | ||
| Li et al. | Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice | |
| Zou et al. | Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice | |
| Song et al. | Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice | |
| Jiao et al. | Blueberry polyphenols extract as a potential prebiotic with anti-obesity effects on C57BL/6 J mice by modulating the gut microbiota | |
| Yuan et al. | Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice | |
| Quezada et al. | Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics | |
| Zhang et al. | Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha | |
| Ge et al. | Effect of industrial trans-fatty acids-enriched diet on gut microbiota of C57BL/6 mice | |
| Chen et al. | Polysaccharides isolated from Cordyceps Sinensis contribute to the progression of NASH by modifying the gut microbiota in mice fed a high-fat diet | |
| Zhou et al. | Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring | |
| Fan et al. | Research progress of gut microbiota and obesity caused by high-fat diet | |
| Kobyliak et al. | Comparative experimental investigation on the efficacy of mono-and multiprobiotic strains in non-alcoholic fatty liver disease prevention | |
| Deng et al. | Hypoglycemic effects of different molecular weight konjac glucomannans via intestinal microbiota and SCFAs mediated mechanism | |
| JP2015523362A5 (enrdf_load_stackoverflow) | ||
| Song et al. | Diet, gut microbiota, and colorectal cancer prevention: a review of potential mechanisms and promising targets for future research | |
| Tang et al. | The therapeutic value of bifidobacteria in cardiovascular disease | |
| Wan et al. | The impact of dietary sn-2 palmitic triacylglycerols in combination with docosahexaenoic acid or arachidonic acid on lipid metabolism and host faecal microbiota composition in Sprague Dawley rats | |
| WO2010136900A3 (en) | Methods of using krill oil to treat risk factors for metabolic disorders and obesity | |
| Deng et al. | Shatianyu (Citrus grandis L. Osbeck) flavonoids and dietary fiber in combination are more effective than individually in alleviating high-fat-diet-induced hyperlipidemia in mice by altering gut microbiota | |
| Villamil et al. | Adverse effect of early-life high-fat/high-carbohydrate (“Western”) diet on bacterial community in the distal bowel of mice | |
| Aoki et al. | Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice | |
| Yang et al. | Enhancing flora balance in the gastrointestinal tract of mice by lactic acid bacteria from Chinese sourdough and enzyme activities indicative of metabolism of protein, fat, and carbohydrate by the flora | |
| WO2011087857A3 (en) | Compositions and methods for treating obesity and diabetes | |
| Aldamarany et al. | Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet |